MX2018012224A - Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas. - Google Patents

Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.

Info

Publication number
MX2018012224A
MX2018012224A MX2018012224A MX2018012224A MX2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A
Authority
MX
Mexico
Prior art keywords
valproic acid
pharmaceutical formulations
delayed release
release pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
MX2018012224A
Other languages
English (en)
Inventor
Bergh Niklas
Jern Sverker
Faijerson SÄLJÖ Jonas
Ove Gustafsson Nils
Roger Marcus Mårtensson Hans
Original Assignee
Cereno Scient Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scient Ab filed Critical Cereno Scient Ab
Publication of MX2018012224A publication Critical patent/MX2018012224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporciona una formulación farmacéutica que tiene uno o más componentes que comprenden ácido valproico (VPA) y/o una sal farmacéuticamente aceptable de este; y uno o más ácidos secundarios, y que comprende opcionalmente uno o más excipientes farmacéuticamente aceptables. También se proporcionan usos de tales formulaciones.
MX2018012224A 2016-04-08 2017-04-10 Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas. MX2018012224A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606197 2016-04-08
PCT/GB2017/051002 WO2017175013A1 (en) 2016-04-08 2017-04-10 Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Publications (1)

Publication Number Publication Date
MX2018012224A true MX2018012224A (es) 2019-05-16

Family

ID=58709491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012224A MX2018012224A (es) 2016-04-08 2017-04-10 Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.

Country Status (15)

Country Link
US (2) US11395808B2 (es)
EP (1) EP3439649B1 (es)
JP (1) JP6985368B2 (es)
KR (1) KR102438395B1 (es)
CN (2) CN114209667A (es)
AU (1) AU2017246697B2 (es)
CA (1) CA3018043A1 (es)
ES (1) ES2969021T3 (es)
HU (1) HUE064701T2 (es)
IL (1) IL262163B2 (es)
MX (1) MX2018012224A (es)
PL (1) PL3439649T3 (es)
RU (1) RU2760304C2 (es)
WO (1) WO2017175013A1 (es)
ZA (1) ZA201806766B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途
CN113995742B (zh) * 2021-10-22 2023-12-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
AT408718B (de) 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
EP1509236A4 (en) 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1937236A2 (en) 2005-09-07 2008-07-02 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
TWI393708B (zh) 2005-09-08 2013-04-21 Mei Pharma Inc 異羥肟酸脂化合物，其用途及其之合成方法
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
PL1815850T3 (pl) * 2006-01-11 2009-05-29 Teva Pharma Preparat kwasu diwalproinowego i jego pochodnych do kontrolowanego uwalniania
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
CN101460197A (zh) 2006-04-06 2009-06-17 诺瓦提斯公司 有机化合物的组合
KR20140114887A (ko) 2006-08-31 2014-09-29 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CN101947209B (zh) * 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
MX2013010329A (es) 2011-03-09 2014-03-12 Sverker Jern Compuestos y metodos para mejorarfibrinolisis endogena deteriorada usando inhibidores de histona deacetilasa.
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
US20200179381A1 (en) 2016-04-08 2020-06-11 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途

Also Published As

Publication number Publication date
AU2017246697B2 (en) 2022-06-02
ZA201806766B (en) 2024-03-27
JP2019510834A (ja) 2019-04-18
RU2018137399A (ru) 2020-05-12
RU2760304C2 (ru) 2021-11-23
HUE064701T2 (hu) 2024-04-28
EP3439649A1 (en) 2019-02-13
IL262163A (en) 2018-11-29
US20230120670A1 (en) 2023-04-20
ES2969021T3 (es) 2024-05-16
KR20180127480A (ko) 2018-11-28
PL3439649T3 (pl) 2024-03-18
WO2017175013A1 (en) 2017-10-12
BR112018070626A2 (pt) 2019-02-05
AU2017246697A1 (en) 2018-10-04
US11395808B2 (en) 2022-07-26
CN109414423A (zh) 2019-03-01
CN114209667A (zh) 2022-03-22
US20190111011A1 (en) 2019-04-18
EP3439649B1 (en) 2023-11-15
KR102438395B1 (ko) 2022-08-30
JP6985368B2 (ja) 2021-12-22
EP3439649C0 (en) 2023-11-15
IL262163B2 (en) 2023-07-01
US12023311B2 (en) 2024-07-02
IL262163B1 (en) 2023-03-01
CA3018043A1 (en) 2017-10-12
RU2018137399A3 (es) 2020-06-18

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
MX2018012224A (es) Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
GEP20237486B (en) Formulations of copanlisib
AU2017277002A1 (en) Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2021016053A (es) Formulaciones de espuma rectal.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
PL419082A1 (pl) Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol
TN2016000561A1 (en) Stabilized desmopressin
EA202090803A1 (ru) Фармацевтическая композиция адапалена и миноциклина для наружного применения
WO2019130301A8 (en) Compositions comprising dead sea extract and an extract of apple of sodom and uses thereof
UA91650U (uk) Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
WO2016112339A8 (en) Stable formulations for the oral administration of amphotericin b and related methods